IQVIA Holdings Inc. $IQV Holdings Trimmed by Vision Capital Management Inc.

Vision Capital Management Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,641 shares of the medical research company’s stock after selling 3,752 shares during the quarter. IQVIA accounts for 0.7% of Vision Capital Management Inc.’s portfolio, making the stock its 29th largest position. Vision Capital Management Inc.’s holdings in IQVIA were worth $6,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in IQVIA by 1.4% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,982 shares of the medical research company’s stock valued at $6,179,000 after buying an additional 314 shares in the last quarter. Grandview Asset Management LLC acquired a new stake in shares of IQVIA during the third quarter worth approximately $310,000. Investment Research Partners LLC increased its holdings in shares of IQVIA by 3.2% during the third quarter. Investment Research Partners LLC now owns 2,294 shares of the medical research company’s stock worth $617,000 after buying an additional 72 shares in the last quarter. Sterling Investment Counsel LLC raised its stake in shares of IQVIA by 2.2% in the third quarter. Sterling Investment Counsel LLC now owns 3,847 shares of the medical research company’s stock valued at $1,034,000 after acquiring an additional 82 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its stake in shares of IQVIA by 12.0% in the third quarter. Vontobel Holding Ltd. now owns 282,916 shares of the medical research company’s stock valued at $76,062,000 after acquiring an additional 30,348 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock opened at $265.72 on Tuesday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $277.40. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm’s 50 day moving average is $261.23 and its 200-day moving average is $213.85. The firm has a market capitalization of $43.74 billion, a price-to-earnings ratio of 32.97, a PEG ratio of 2.32 and a beta of 1.17.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business posted $2.81 earnings per share. IQVIA’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research analyst reports. Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. William Blair raised IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $276.00.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. Corporate insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.